新辅助内分泌治疗对于高危前列腺癌根治术"三连胜"效果的影响评价  

Evaluation of the effect of neoadjuvant hormone therapy on the"trifecta"of radical surgery for high-risk prostate cancer

作　　者：刘骏锋 周术奎 刘磊 唐多才 张桂银 李曾[2] 杨盛柯 陈勇吉 廖洪[2] Liu Junfeng;Zhou Shukui;Liu Lei;Tang Duocai;Zhang Guiyin;Li Zeng;Yang Shengke;Chen Yongji;Liao Hong(School of Clinical Medicine,Chengdu Medical College,Chengdu 610500,China;Department of Urology,Sichuan Clinical Research Center for Cancer(Sichuan Cancer Hospital&Institute,Sichuan Cancer Center,Affiliated Cancer Hospital of University of Electronic Science and Technology of China),Chengdu 610041,China)

机构地区：[1]成都医学院临床医学院,成都610500 [2]四川省肿瘤临床医学研究中心(四川省肿瘤医院研究所,四川省癌症防治中心,电子科技大学附属肿瘤医院)泌尿外科,成都610041

出　　处：《国际泌尿系统杂志》2024年第5期805-809,共5页International Journal of Urology and Nephrology

摘　　要：目的探讨新辅助内分泌治疗(NHT)对高危前列腺癌根治术(RP)后"三连胜"效果的影响。方法回顾性分析2015年5月至2022年3月在四川省肿瘤医院行RP的62例高危前列腺癌(PCa)患者的临床资料,将其中31例RP术前行NHT患者设为新辅助组,另外31例行RP患者设为对照组。比较两组的围手术期情况、肿瘤控制情况、排尿功能恢复情况、术后性功能等。结果新辅助组的术后切缘阳性率、病理降期率明显优于对照组,差异均有统计学意义(均P<0.05)。两组的术后即刻、3、6、12个月尿失禁恢复、性功能恢复及无生化复发时间比较,差异均无统计学意义(均P>0.05)。结论新辅助内分泌治疗可显著降低手术切缘阳性、实现病理降期,使部分患者的病理完全缓解,在肿瘤控制方面有明显获益,是高危PCa患者可供选择的治疗方式。ObjectiveTo investigate the effects of neoadjuvant hormonal therapy(NHT)on the"trifecta"outcomes post-radical prostatectomy(RP)in high-risk prostate cancer patients.MethodsA retrospective analysis was conducted on the clinical data of 62 high-risk prostate cancer(PCa)patients who underwent RP in Sichuan Cancer Hospital from May 2015 to March 2022.Among them,31 patients received NHT as the neoadjuvant group,while the remaining 31 patients who underwent RP without NHT served as the control group.Perioperative conditions,tumor control,urinary function recovery,and postoperative sexual function were compared between the two groups.ResultsThe neoadjuvant group had a significantly lower positive margin rate and a higher pathologic downstaging rate compared to the control group,with statistically significant differences(all P<0.05).There were no statistically significant differences observed in the recovery time of urinary continence,sexual function,and biochemical relapse-free rates between the two groups immediately after surgery,as well as at 3,6,and 12 months post-surgery(all P>0.05).ConclusionsNeoadjuvant hormonal therapy can significantly reduce positive surgical margins and achieve pathologic downstaging,leading to complete pathologic remission in some patients.It offers clear benefits in tumor control and is a viable treatment option for high-risk PCa patients.

关 键 词：前列腺肿瘤 新辅助治疗 前列腺癌根治术 

分 类 号：R737.25[医药卫生—肿瘤]